Literature DB >> 30126298

Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018.

Nami Okamoto1, Shumpei Yokota2, Syuji Takei3, Yuka Okura4, Tomohiro Kubota3, Masaki Shimizu5, Tomo Nozawa6, Naomi Iwata7, Hiroaki Umebayashi8, Noriko Kinjo9, Tomoko Kunishima9, Junko Yasumura10, Masaaki Mori11.   

Abstract

Juvenile idiopathic arthritis (JIA) is the most common disease in pediatric rheumatism. There is no specific symptom or examination finding for JIA, and the diagnosis is made by exclusion and differentiation. Because non-pediatric rheumatologists are sometimes involved in medical care, 'proposal for JIA guidance on diagnosis and treatment for primary care pediatricians and non-pediatric rheumatologists' was first published in 2007. In these 10 years, a number of new findings on pathophysiology and treatment of JIA have been published; therefore, we propose this guidance of 2018th edition aiming at updating and standardization of JIA medical care in Japan. This edition included the management of uveitis, macrophage activation syndrome, infectious diseases before and during treatment. Moreover, details of biologics are also described. Although this guidance is tailored to adaptation of examinations and drugs, we do not purpose to limit the physicians' discretion in clinical practice. This guidance should be viewed as recommendations and be individualized according to the condition of the patient. We hope that medical care for JIA will advance and more patients will get benefit based on this guidance. Then, further revisions are needed due to changes in future conditions.

Entities:  

Keywords:  Juvenile idiopathic arthritis; algorism of treatment; biologics; clinical practice guidance; macrophage activation syndrome; uveitis

Mesh:

Substances:

Year:  2018        PMID: 30126298     DOI: 10.1080/14397595.2018.1514724

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  5 in total

1.  [Clinical characteristics and biological treatment of adult patient with juvenile idiopathic arthritis].

Authors:  S X Wei; S J Li; Y Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

2.  An Integrative Transcriptomic Analysis of Systemic Juvenile Idiopathic Arthritis for Identifying Potential Genetic Markers and Drug Candidates.

Authors:  Daeun Kim; Jaeseung Song; Sora Lee; Junghyun Jung; Wonhee Jang
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

3.  Non-disease specific patient-reported outcome measures of health-related quality of life in juvenile idiopathic arthritis: a systematic review of current research and practice.

Authors:  Justyna Młyńczyk; Paweł Abramowicz; Maciej K Stawicki; Jerzy Konstantynowicz
Journal:  Rheumatol Int       Date:  2021-12-31       Impact factor: 2.631

4.  Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database.

Authors:  Takeo Hata; Atsushi Hirata; Ryosuke Ota; Keiko Hosohata; Masami Nishihara; Masashi Neo; Takahiro Katsumata
Journal:  Ther Clin Risk Manag       Date:  2022-08-24       Impact factor: 2.755

Review 5.  Juvenile Idiopathic Arthritis: A Review of Novel Diagnostic and Monitoring Technologies.

Authors:  Amelia J Garner; Reza Saatchi; Oliver Ward; Daniel P Hawley
Journal:  Healthcare (Basel)       Date:  2021-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.